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Manuscript rece
accepted August 1irst-generation drug-eluting stents (DES), which impart the controlled release of sirolimus or paclitaxel from durable
polymers to the vessel wall, have been consistently shown to reduce the risk of restenosis and target vessel
revascularization compared with bare metal stents (BMS). However, stent thrombosis (ST) emerged as a major
safety concern with ﬁrst-generation DES early after their adoption in clinical practice, requiring prolonged dual
antiplatelet therapy. Pathological studies have shown that ﬁrst-generation DES are associated with delayed arterial
healing and polymer hypersensitivity reactions resulting in chronic inﬂammation, predisposing to late and very late
ST. Second-generation DES have been developed to overcome these issues with improved stent designs and
construction and the use of biocompatible and bioabsorbable polymers. Meta-analyses have shown that the thin-
strut, ﬂuoropolymer-coated cobalt-chromium everolimus-eluting stent (CoCr-EES) may be associated with lower rates
of deﬁnite ST than other DES and, unexpectedly, even lower than BMS. The thin-strut structure of the stent platform,
the thromboresistant properties of the ﬂuoropolymer, and the reduced polymer and drug load may contribute to the
low rate of ST with CoCr-EES. The notion of DES being safer than BMS represents a paradigm shift in the evolution of
percutaneous coronary intervention. The relative safety and efﬁcacy of ﬂuoropolymer-coated CoCr-EES, DES with
bioabsorbable polymers, and fully bioresorbable scaffolds are the subject of numerous ongoing large-scale trials.
(J Am Coll Cardiol 2013;62:1915–21) ª 2013 by the American College of Cardiology FoundationAlthough ﬁrst-generation Cypher sirolimus-eluting stents
(SES) (Cordis Corp., Miami Lakes, Florida) and Taxus
paclitaxel-eluting stents (PES) (Boston Scientiﬁc, Natick,
Massachusetts) signiﬁcantly reduce the risk of target vessel
revascularization compared with bare-metal stents (BMS)
(1,2), concern has been raised over their ongoing propensity
for very late stent thrombosis (ST) (3). These safety concerns
prompted the development of second-generation drug-
eluting stents (DES), which use different drugs, more
biocompatible or bioabsorbable polymers, and different stent
platforms. On their introduction, second-generation DES
were most commonly compared with ﬁrst-generation DES
in noninferiority randomized controlled trials (RCTs) (4),
which did not have sufﬁcient statistical power to explore
possible differences in ST rates between devices. In this re-
view, we therefore analyze the relative risk of ST, death, and
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2, 2013.generation DES, and BMS that have been extensively
investigated in RCTs.We did not analyze in detail all studies
enrolling patients with ST-segment elevation MI because
this issue was recently addressed by a dedicated analysis (5).ST With First-Generation DES
Although RCTs initially did not raise any safety issues with
ﬁrst-generation DES (1,2), a subsequent report of 4 cases of
angiographically conﬁrmed ST late after elective implantation
of SES or PES raised concerns of a possible very late ST risk
with DES (6). However, it was not until 2006, at the annual
meeting of the European Society of Cardiology in Barcelona,
that the ﬁrestorm over ﬁrst-generation DES was ignited,
spreading concern among the media and public as well as
interventional cardiologists (7). During this congress, a meta-
analysis performed on aggregate data pooled from trial
programs comparing SES or PES versus BMS suggested an
increased risk of mortality and MI with ﬁrst generation DES
compared to BMS (8). The controversy regarding the safety of
DES was fueled by additional real-world studies that showed
an increased risk of late ST and MI in patients treated with
ﬁrst-generationDES after discontinuation of dual antiplatelet
therapy (DAPT) (3) and a steady accrual of ST at a rate of 0.6%
per year with no evidence of plateau after 4-year follow-up (9).
Pathological studies showed that the durable polymer of
ﬁrst-generation DES could result in chronic inﬂammation,
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1916with delayed hypersensitivity re-
actions, chronic ﬁbrin deposition,
and consequent poor endothelial
healing of the vessel wall with
increased thrombotic risk (10).
In view of the rare incidence
of ST and the conﬂicting evi-
dence, several pooled analyses
and meta-analyses were perfor-
med to address the safety of
ﬁrst-generation DES (11–14). As
shown in Table 1, these studies
collectively established no signiﬁ-
cant differences in the risk of death
or MI between ﬁrst-generation
DES and BMS but an increased
risk of very late ST with both SES
and PES compared with BMS.
On the basis of this mounting
evidence regarding the ongoing
propensity of DES ST over time,
the Food and Drug Administra-
tion (FDA) assigned an expert
panel to review the available
evidence. Eventually, the advisory
panel released a statement ac-
knowledging a small but signiﬁ-
cant increased risk of very late ST
with DES while recognized them
as safe and effective for on-label
indications (15). The absence ofa signiﬁcant difference in mortality or MI between ﬁrst-
generation DES and BMS despite the increased risk of very
late ST with DES may be explained by the fact that in-stent
restenosis is not always a benign phenomenon, presenting as
acute MI in 3.5% to 19.4% of patients (16). Thus, a small
increase in a low-frequency event (late or very late ST) with
frequent, serious, life-threatening consequences may be offset
by a large reduction of a more common event (restenosis),
which is occasionally but less frequently associated with serious
clinical consequences (17).
Nonetheless, responding to the general concerns of
increased ST with DES, the FDA and societies recom-
mended lengthening the requirement for DAPT after DES
from 3 to 6 months (as studied in the pivotal approval trials)
to 1 year, although little data supported this extension.
The Academic Research Consortium
Deﬁnition of ST
The lack of a uniform deﬁnition of ST provided signiﬁcant
uncertainty in the comparative interpretation of the results
of clinical trials and meta-analyses. To standardize deﬁni-
tions for patients enrolled in cardiovascular trials, a formal
collaboration between academic research organizations in
the United States and Europe, the Academic ResearchConsortium (ARC), was established (18). Using ARC
criteria, ST is deﬁned according to various levels of
certainty, depending on whether the level of evidence needs
to be more or less restrictive (18). ST is also classiﬁed
relative to the timing of occurrence after stent implantation
as early (within 30 days), late (between 30 days and 1 year)
and very late (beyond 1 year). Mauri et al. (19) were the
ﬁrst to analyze the risk of ST using both the trial protocol
deﬁnitions of ST and the ARC criteria in a meta-analysis.
At 4-year follow-up, there were no signiﬁcant differences
in the risk of ST between either SES or PES and BMS,
but a different temporal trend in the risk of ST was
apparent depending on whether the protocol deﬁnition or
the ARC criteria were used to deﬁne ST. In the Stettler
meta-analysis, using mixed treatment comparisons and
comparing outcomes of PES, SES, and BMS, the authors
reported that mortality was similar in the 3 groups, SES
was associated with signiﬁcantly lower rates of MI than
both BMS and PES, and PES was associated with
signiﬁcantly higher rates of late plus very late deﬁnite ST
than both SES and BMS.
ST With Second-Generation DES
Second-generation DES have been developed with advanced
design features, speciﬁcally thinner strut stent platforms (most
commonly using a cobalt-chromium alloy) and more biocom-
patible polymers or bioabsorbable polymers. FDA-approved
second-generation DES currently in use include Xience V,
Xience Prime, and Xience Expedition (Abbott Vascular,
Santa Clara, California), which are cobalt-chromium ever-
olimus-eluting stents (CoCr-EES); Promus Element (Boston
Scientiﬁc, Natick, Massachusetts), a platinum-chromium
everolimus-eluting stent (PtCr-EES); Endeavor (Medtronic,
Santa Rosa, California), a phosphorylcholine polymer-
based fast-release zotarolimus-eluting stent (PC-ZES);
and Resolute (Medtronic), a C10/C19/PVP polymer-based
slow-release zotarolimus-eluting stent (Re-ZES) (Table 2).
CoCr-EES have undergone the most extensive clinical
investigation. RCTs and observational studies have consis-
tently shown low rates of ST with CoCr-EES, with some
studies showing signiﬁcantly lower rates of ST with CoCr-
EES than with PES or SES (4,20,21). However, all these
studies were insufﬁciently powered to reliably detect differ-
ences in ST, and therefore several meta-analyses have been
performed to address this issue (Table 1). In the meta-
analysis by Baber at al. in which 13 RCTs with 17,101
patients were included, CoCr-EES signiﬁcantly reduced
deﬁnite/probable ST and MI compared with pooled PES,
SES, and Re-ZES after a median follow-up of 21 months
(22). However, treatment effects for each endpoint varied by
DES comparator, with the largest difference apparent for
CoCr-EES versus PES, intermediate for CoCr-EES versus
Re-ZES, and smallest for CoCr-EES versus SES. In the
meta-analysis by de Waha et al. (23) in which CoCr-EES
were compared with SES in 5 RCTs with 7,370 patients,
Table 1 Main Meta-Analyses Comparing Clinical Outcomes With Different Types of Drug-Eluting Stents and Bare-Metal Stents
First Author, Year
No. of
Studies
No. of
Patients DES Comparators
Length of
Follow-Up
Main Results for
Death and MI Main Results for ST
Per-protocol deﬁnition
of ST
Stone, 2007 9 5,261 BMS/PES/SES 4 yrs No difference Increased rates of very late ST with SES
or PES compared with BMS
Ellis, 2007 4 3,445 BMS/PES 3 yrs NA Increased rates of ST between
6 months and 3 yrs with PES
compared with BMS
Kastrati, 2007 14 4,958 BMS/SES 5 yrs No difference No difference
ARC deﬁnition of ST
with ﬁrst-
generation DES
Mauri, 2007 8 4,545 BMS/PES/SES 4 yrs NA No difference
Stettler, 2007 38 18,023 BMS/PES/SES 4 yrs Lower rates of MI with
SES than BMS or PES
Increased rates of late and very late ST
with PES compared with both SES
and BMS
No difference between SES and BMS
ARC deﬁnition of ST
with second-
generation DES
Baber, 2011 13 17,101 CoCr-EES vs. pooled
PES, SES, and Re-ZES
21 months* Lower rates of MI with
CoCr-EES compared
with pooled other DES
Lower rates of ST with CoCr-EES
compared with pooled other DES
De Waha, 2012 8 11,167 CoCr-EES vs. SES 13 months* No difference Trend for lower rates of ST with
CoCr-EES
Palmerini, 2012 11 16,775 CoCr-EES vs. pooled
PES, SES, and Re-ZES
2 yrs NA Lower rates of ST with CoCr-EES
compared with pooled other DES
Palmerini, 2012 49 50,844 BMS/PES/SES/
CoCr-EES/PtCr-EES/
Re-ZES/PC-ZES
2 yrs NA Lower rates of ST with CoCr-EES than
BMS and PES
Bangalore, 2012 77 117,762 BMS/PES/SES/EES/
Re-ZES/PC-ZES
2.1 yrs* Lower rates of MI with SES,
ZES, and CoCr-EES but
not with PES compared
with BMS
Lower rates of ST with CoCr-EES
compared with other DES and BMS
*Median follow-up.
ARC ¼ Academic Research Consortium; BMS ¼ bare-metal stent(s); CoCr-EES ¼ cobalt-chromium everolimus-eluting stent(s); DES ¼ drug-eluting stent(s); MI ¼ myocardial infarction; NA ¼ not available;
PC-ZES ¼ phosphorylcholine polymer-based zotarolimus-eluting stent(s); PES¼ paclitaxel-eluting stent(s); Re-ZES¼ Resolute zotarolimus-eluting stent(s); SES¼ sirolimus-eluting stent(s); ST¼ stent thrombosis.
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1917no signiﬁcant differences in the risks of death,MI, or deﬁnite/
probable ST were apparent between CoCr-EES and SES
after a median follow-up of 13.3 months, although a trend
toward a reduction in deﬁnite/probable ST was apparent in
favor of CoCr-EES (23).Table 2 Current FDA-Approved Drug-Eluting Stents
Commercial Name Manufacturer
Drug Released
(Concentration mg/cm2) Kinetic of Dr
Taxus Express
Taxus Liberté
Boston
Scientiﬁc
Paclitaxel (100) 10% during the
10 days*
Cypher Cordis Sirolimus (140) 80% during the
Endeavor Medtronic Zotarolimus (160) 80% during the
10 days
Resolute Medtronic Zotarolimus (160) 80% during the
2 months
Xience V
Xience Prime
Xience Expedition
Abbott
Vascular
Everolimus (100) 80% during the
Promus Element Boston
Scientiﬁc
Everolimus (100) 80% during the
*The remaining 90% of the drug remains sequestered in the polymer indeﬁnitely.
FDA¼ Food and Drug Administration; HPMA ¼ hydroxypropyl methacrylate; LMA ¼ lauryl methacrylate
PBMA ¼ poly(n-butyl methacrylate); PEVA ¼ poly(ethylene-co-vinyl acetate); PHMA ¼ poly(hexyl me
ﬂuoropropylene; PVP ¼ polyvinylpyrrolidone; SIBS ¼ poly(styrene-b-isobutylene-b-styrene).These 2 meta-analyses were limited by the facts that they
examined ST using the broad deﬁnition of deﬁnite/probable
ST, rather than the more speciﬁc criteria used to deﬁne
deﬁnite ST, and considered only one speciﬁc time
point, thus leaving undetermined whether there might beug Release Polymer Platform
Strut Thickness
(mm)
ﬁrst SIBS Stainless steel 132
97
ﬁrst month PEVA, PMA Stainless steel 140
ﬁrst MPC, LMA, HPMA,
3-MPMA
Cobalt-chrome 91
ﬁrst PBMA, PHMA, PVP, PVA Cobalt-chrome 91
ﬁrst month PBMA, PVDF-HFP Cobalt-chrome 81
ﬁrst month PBMA, PVDF-HFP Platinum-
chrome
81
; MPC ¼ methacryloyloxyethyl phosphorylcholine; 3-MPMA ¼ 3-(trimethoxysilyl)propyl methacrylate;
thacrylate); PVA ¼ polyvinyl acetate; PVDF-HFP ¼ copolymer of vinylidene ﬂuoride and hexa-
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1918time-related differences in the risk of ST between various
devices. To address these issues, Palmerini et al. performed
a meta-analysis of 11 RCTs with 16,775 patients (including
5 trials of CoCr-EES vs. PES, 5 trials of CoCr-EES vs.
SES, and 1 trial of CoCr-EES vs. Re-ZES) (24). This study
showed signiﬁcantly lower rates of early, late, 1-year, and 2-
year deﬁnite ST with CoCr-EES compared with other
pooled DES, with no interaction apparent between the
overall relative risk of deﬁnite ST and any DES comparator.
The reduced risk of ST with CoCr-EES compared with
ﬁrst-generation DES suggested by these meta-analyses has
since been conﬁrmed in “real-world” studies. Speciﬁcally,
with a median follow-up of 1.5 years in 1,342 propensity
score-matched pairs of patients, CoCr-EES were found to
have signiﬁcantly lower rates of deﬁnite ST and MI
compared with SES (20). Moreover, in a large all-comers
study including 12,339 patients, the rates of deﬁnite ST
were lower with CoCr-EES than either SES or PES up to
4-year follow-up, with differences in ST most pronounced
after the ﬁrst year from stent implantation (21).
PC-ZES represents the combination of zotarolimus,
a low-proﬁle cobalt alloy stent platform, and a biocompatible
phosphorylcholine polymer as a drug carrier system. In the
Endeavor clinical trials program, PC-ZES was com-
pared with BMS (ENDEAVOR II) (25), with SES
(ENDEAVOR III) (26), and with PES (ENDEAVOR IV)
(27). Although no signiﬁcant difference in the risk of ST
between PC-ZES and either of these stent comparators
emerged in these trials, some studies have suggested lower
rates of death and MI with PC-ZES than SES (26) or PES
(27), whereas other studies have refuted this association (28).
More recently, in the large-scale, multicenter, randomized
PROTECT (PROphylaxis for ThromboEmbolism in
Critical Care Trial), in which 8,800 patients with coronary
artery disease were enrolled (the largest comparative DES
trial to date), no signiﬁcant differences in death, MI, or ST
were apparent between patients with SES (n ¼ 4,400) and
PC-ZES (n ¼ 4,440). Notably, however, patients with SES
tended to have less deﬁnite/probable ST in the ﬁrst year
than PC-ZES (p ¼ 0.06), while very late ST rates between
the ﬁrst and third year were greater with SES than PC-ZES
(1.1% vs. 0.3%; p < 0.001) (29).
Re-ZES uses the same stent platform as PC-ZES but
incorporates a different polymer system (BioLinx; Med-
tronic Vascular), a composite polymer with hydrophilic and
hydrophobic layers that allows a more delayed release of
the same zotarolimus concentration as in the original En-
deavor stent. Re-ZES has been compared with CoCr-EES in
the RESOLUTE-AC (Two-arm, Non-inferiority Study
Comparing Resolute Stent With Xience-V Stent) (30) and
TWENTE (The Real-World Resolute Versus XIENCE V
Drug-Eluting Stents Study in Twente) trials (31). In both
studies, no signiﬁcant differences in rates of death orMI were
apparent between the 2 stents. However, deﬁnite ST at 1 year
was signiﬁcantly less frequent with CoCr-EES than Re-ZES
in the RESOLUTE-AC trial (0.3% vs. 1.2%, respectively;p ¼ 0.01) (30) and numerically lower in the TWENTE trial
(0% with Xience vs. 0.6% with Re-ZES; p ¼ 0.12) (31).
When the broader deﬁnition of deﬁnite/probable ST was
considered, a borderline statistical reduction in ST was
apparent with CoCr-EES compared with Re-ZES in the
RESOLUTE-AC trial (0.7% vs. 1.6%, respectively; p ¼
0.05), whereas numerically higher rates of deﬁnite/probable
ST were apparent with CoCr-EES compared with Re-ZES
in the TWENTE trial (1.2% vs. 0.9%, respectively; p¼ 0.59).
ST With Second-Generation DES Versus BMS:
Network Meta-Analyses
Because most second-generation DES were approved in non-
inferiority trials compared with ﬁrst-generation DES,
few studies have directly compared second-generation DES
with BMS. Recently, the EXAMINATION (A Clinical
Evaluation of Everolimus Eluting Coronary Stents in the
Treatment of Patients With ST-segment Elevation Myo-
cardial Infarction) trial, in which 1,504 patients with ST-
segment elevation MI were randomized to CoCr-EES versus
BMS, showed signiﬁcantly lower rates of ST in patients treated
with CoCr-EES (32). However, this trial was not powered to
determine differences in ST (and this hypothesis was not pre-
speciﬁed), and therefore a type I error cannot be excluded.
Network meta-analysis and mixed treated comparisons
are novel research methods capable of comparing different
treatments using a common reference treatment, and their
role in clinical research has been established (33). Two
network meta-analyses have assessed the relative safety and
efﬁcacy of currently available DES and BMS (34,35). In a
network meta-analysis that included 49 RCTs with 50,844
patients, Palmerini et al. investigated the risk of ST bet-
ween FDA-approved DES (Xience/Promus, Endeavor,
Resolute, Promus Element, Cypher, and Taxus) and BMS,
analyzing the risk of deﬁnite and deﬁnite/probable ST at
1 and 2 years and in the early, late, and very late periods
(35). Only studies reporting ST according to the ARC
criteria were included. As shown in Figure 1, CoCr-EES
were associated with signiﬁcantly lower rates of 1-year
and 2-year deﬁnite ST than BMS, a result not observed
with other DES; the reduction in ST with CoCr-EES
compared with BMS was apparent both early and late
(occurring before 30 days and between 31 days and 1 year);
and CoCr-EES were also associated with signiﬁcantly
lower 1-year rates of deﬁnite ST compared with other ﬁrst-
and second-generation DES, including PES, SES, PC-
ZES, and Re-ZES. Potentially the most important and
unexpected ﬁnding was the signiﬁcantly lower risk of ST
with CoCr-EES compared with BMS at 1-year and 2-year
follow-up. A signiﬁcant difference in deﬁnite ST between
CoCr-EES and BMS was already apparent at 30 days and
was also present in the period between 31 days and 1 year.
These differences were also seen for the more sensitive but
less speciﬁc deﬁnition of ARC deﬁnite/probable ST for up
to 2 years of follow-up.
Figure 1
Pooled Odds Ratio and 95% Credible Intervel Determined by Network Meta-Analysis for the Risk of Deﬁnite Stent Thrombosis
at Various Time Points
Only statistically signiﬁcant results are shown. (A) 1-year odds ratio of deﬁnite stent thrombosis; (B) 2-year odds ratio of deﬁnite stent thrombosis; (C) odds ratio of early deﬁnite
stent thrombosis; (D) odds ratio of late deﬁnite stent thrombosis. BMS ¼ bare-metal stent(s); CI ¼ credible interval; CoCr-EES ¼ cobalt-chromium everolimus-eluting stent(s);
PC-ZES ¼ phosphorylcholine polymer-based zotarolimus-eluting stent(s); PES ¼ paclitaxel-eluting stent(s); PtCr-EES ¼ platinum-chromium everolimus-eluting stent(s); Re-ZES ¼
Resolute zotarolimus-eluting stent(s); SES ¼ sirolimus-eluting stent(s); Reprinted with permission from Palmerini et al. (35).
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et al. included 77 RCTs with 117,762 patients. In that study,
study selection was not restricted to FDA-approved brands or
to RCTs reporting ST according to the ARC criteria as in the
previous network meta-analysis (34). Although rates of long-
term mortality were similar between ﬁrst-generation DES,
second-generation DES, and BMS, rates of MI were
signiﬁcantly lower with SES, ZES, and CoCr-EES but not
with PES compared with BMS. Data on ST, both per
protocol or by ARC criteria, were consistent with the previous
network meta-analysis, showing lower deﬁnite ST rates with
CoCr-EES compared with other DES and BMS (35).
Although meta-analyses inherently contain ﬂaws and
should be considered hypothesis generating, the lack of
heterogeneity across most of the included RCTs, the
stability of results in several sensitivity analyses, and the
consistency between direct and indirect estimates apparent
in these network meta-analyses provide strong support
of their ﬁndings, suggesting a paradigm shift from thecontention of an increased risk of ST with DES compared
with BMS to the converse. A large randomized trial of CoCr-
EES (or other DES) compared with BMS powered for ST
would be required for deﬁnitive proof of this hypothesis,
however. Such a study is unlikely to be performed except
possibly in patients with ST-segment elevation MI. More-
over, it should be underscored that CoCr-EES is the most
extensively studied second-generation DES; other second-
generation DES such as PtCr-EES or Re-ZES have been
less intensely studied in terms of the number of clinical trials
performed and the length of follow-up available. Further
studies are therefore needed to clarify the relative safety and
efﬁcacy of different second-generation DES.
Mechanistic Underpinnings of Reduced ST With
Second-Generation DES
Animal and human studies have identiﬁed non-
erodable polymer coatings as a possible factor triggering
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1920hypersensitivity reactions, chronic inﬂammation, and
persistent ﬁbrin deposition, causing impaired endothelial
healing and predisposition to very late ST (10). The fact
that CoCr-EES compared with other DES and BMS
have resulted in lower rates of ST in both the early as well
as the late period (35) is of relevance when considering the
potential mechanisms of this protective effect, which likely
include more rapid and complete endothelialization as
well as differences in stent alloy and architecture, strut
thickness, polymer characteristics, and antiproliferative
drug type, dose, and release kinetics. Speciﬁcally, the thin
(81 mm), malleable cobalt-chromium stent struts, the
thromboresistant ﬂuorocopolymer (13,36), and the low
polymer and drug load may contribute to the low rate of
ST observed with CoCr-EES. The concept of a polymer-
coated DES being safer than BMS is supported by the
experimental studies of Kolandaivelu et al. (13), in which
ﬂuoropolymer-coated stents had signiﬁcantly lower
thrombosis and platelet deposition compared with their
bare metal counterparts. In this regard, ﬂuoro-copolymers
have been shown to elicit reduced platelet aggregates in
blood contact applications (36). Whether similar proper-
ties are shared by other second-generation DES deserves
further investigation.
Implications and Future Directions
The protective effect exerted by ﬂuorocopolymers on ST
challenges the notion that bioabsorbable polymers or bio-
absorbable vascular scaffolds may be necessary to minimize
ST; indeed, the durable polymer in this instance may be
beneﬁcial. In this regard, whereas studies have suggested lower
rates of STwithDESusing bioabsorbable polymers compared
with permanent polymer SES only in the very late period (37),
CoCr-EES have been associated with reduced rates of ST in
the early, late, and very late periods compared with BMS and
other ﬁrst- and second-generation DES (24,35). Therefore,
while the advantages of bioabsorbable polymer-based DES
over ﬁrst-generation permanent polymerDES are expected to
emerge in the late follow-up period after biodegradation of the
polymer, the presence of the thromboresistant ﬂuoropolymer
may reduce the risk of ST both in the early and late period.
Large comparative trials of durable ﬂuoropolymer-coated
DES, bioabsorbable polymer-based DES, and fully bio-
resorbable scaffolds will be necessary to truly characterize the
relative safety proﬁles of these very different classes of devices.
Some such studies are ongoing, and others are being planned.
The lower risk of late ST with second-generation DES
compared with ﬁrst-generation DES also challenges current
guidelines that recommend 1 year of DAPT after DES
placement (38). This recommendation was not based on
speciﬁc evidence-based randomized trial results, but rather
relied on post-hoc analyses of observational studies performed
with ﬁrst-generation DES (3). More recently, a post-hoc
analysis of pooled data from the SPIRIT II, III, and IV and
COMPARE trials has suggested that interruption of DAPT3 months after percutaneous coronary intervention (PCI) with
CoCr-EESdoes not carry an increased hazard of ST compared
with never interrupting DAPT up to 1 year (39). Moreover, in
post-hoc analyses of real-world studies performed in the
XienceVprogram(SPIRITV,SPIRITWOMEN,XIENCEV
USA, andXIENCEVIndia) including 10,615patients treated
with CoCr-EES, there were no episodes of ST up to 1-year
follow-up in patients who discontinued DAPT between
3 and 12 months (40). Similar ﬁndings were apparent
when another second-generation DES (Re-ZES) was
considered. Speciﬁcally, in a substudy of theRESOLUTE-AC
trial, among the 851 patients with a ﬁrst interruption ofDAPT
beyond3months, therewerenoSTevents at 1 year (41). Future
RCTs should investigate whether 3-month DAPT is as
effective (and potentially safer, with less bleeding) as 12-month
DAPT in patients treated with second-generation DES.
Similarly, important trials completed in the past decade that
have examined the relative risks and beneﬁts of PCI versus
medical therapy in stable coronary artery disease (42) and PCI
versus coronary artery bypass grafting in complex coronary
artery disease (43) have exclusively used ﬁrst-generation DES
or BMS.Themajor generational advances in stent technology
with attendant improvements in patient outcomes need to be
carefully considered when interpreting the clinical implica-
tions of trials. It is a reality that major guidelines committees
must rely on out-of-date studies when making recommen-
dations.Major advances in therapies require new comparative
trials. One such ongoing large-scale trial, EXCEL, is
randomizing 2,600 patients with unprotected left main
coronary artery disease and a low to intermediate Syntax score
to coronary surgery versus PCI with CoCr-EES.
Conclusions
Compared with ﬁrst-generation DES, second-generation
DES show signiﬁcantly enhanced safety, representing a major
advance for patients with coronary artery disease requiring
revascularization.
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